Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

OBJECTIVE: To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1β antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Twenty patients (aged 7–78 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Gattorno, Marco, Obici, Laura, Cattalini, Marco, Tormey, Vincent, Abrams, Ken, Davis, Nicole, Speziale, Antonio, Bhansali, Suraj G, Martini, Alberto, Lachmann, Helen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264215/
https://www.ncbi.nlm.nih.gov/pubmed/27269295
http://dx.doi.org/10.1136/annrheumdis-2015-209031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264215/
https://www.ncbi.nlm.nih.gov/pubmed/27269295
http://dx.doi.org/10.1136/annrheumdis-2015-209031

Ejemplares similares